Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Claudin 6-targeting CAR-T
- Development stage
- Preclinical
- Lead developer
- BioNTech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Claudin 6-targeting CAR-T is a preclinical-stage chimeric antigen receptor T-cell (CAR-T) therapy being developed by Innovative Cellular Therapeutics (also known as Shanghai Si Dan Race BioTechnology) for the treatment of ovarian cancer. The therapy consists of autologous T cells genetically engineered to express a CAR targeting Claudin 6 (CLDN6), a tight junction membrane protein that is highly overexpressed in various solid tumors, including ovarian cancer, while showing restricted expression in healthy adult tissues. Upon administration, these CAR-T cells specifically bind to CLDN6-expressing tumor cells, leading to T-cell activation, proliferation, and targeted tumor cell lysis.
- Other names
- CLDN6 CAR-TCLDN-6 CAR-TCLDN 6 CAR-TClaudin-6 CAR-TClaudin6 CAR-TClaudin 6 CAR-Tanti-CLDN6 CAR-Tanti-CLDN-6 CAR-Tanti-CLDN 6 CAR-T
02
Targets
CLDN6 (Claudin-6)
Beyond the preview
Go deeper on Claudin 6-targeting CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Claudin 6-targeting CAR-T.